US Capitol Capsule: Don't Make Assumptions On Biosimilars Actions, FDA Official Warns

While FDA action dates may have come and gone on some biosimilar applications, known as 351(k)s, it would be wrong to make an assumption regulators had issued a complete response letter (CRL) due to the lack of biosimilarity, warned Leah Christl, associate director for therapeutic biologics.

While FDA action dates may have come and gone on some biosimilar applications, known as 351(k)s, it would be wrong to make an assumption regulators had issued a complete response letter (CRL) due to the lack of biosimilarity, warned Leah Christl, associate director for therapeutic biologics.

"As a general matter, for any application, there's a number of things that could create a bump in the road,"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

More from Therapy Areas